453 related articles for article (PubMed ID: 32244396)
21. The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.
Lee J; Lozano-Ruiz B; Yang FM; Fan DD; Shen L; González-Navajas JM
Front Immunol; 2021; 12():625667. PubMed ID: 33777008
[TBL] [Abstract][Full Text] [Related]
22. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
23. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
Gascón M; Isla D; Cruellas M; Gálvez EM; Lastra R; Ocáriz M; Paño JR; Ramírez A; Sesma A; Torres-Ramón I; Yubero A; Pardo J; Martínez-Lostao L
Cells; 2020 Jun; 9(6):. PubMed ID: 32580514
[TBL] [Abstract][Full Text] [Related]
25. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
26. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
28. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
29. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
Benitez JC; Recondo G; Rassy E; Mezquita L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):162-174. PubMed ID: 32107903
[TBL] [Abstract][Full Text] [Related]
30. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
31. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
33. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
Front Immunol; 2020; 11():223. PubMed ID: 32133005
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Meyers DE; Banerji S
Curr Oncol; 2020 Apr; 27(Suppl 2):S106-S114. PubMed ID: 32368180
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
37. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
38. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
Voutsadakis IA
Chin Clin Oncol; 2020 Apr; 9(2):19. PubMed ID: 32279524
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
